Company Information

  

Address: ONE FIRST AVENUE
PARRIS BUILDING 34, NAVY YARD PLAZA 
City: BOSTON 
State: MA 
Zip Code: 02129 
Telephone: 617-259-1970 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Ziopharm Oncology, Inc. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing next generation immunotherapy platforms that leverage gene- and cell-based therapies to treat patients with cancer on its own and with partners. We are developing two immuno-oncology platform technologies designed to utilize the patient's immune system by employing novel, controlled gene expression and innovative cell engineering technologies to deliver safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. Our first platform is Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-0.53NAN/E
12/2017-0.53NAN/E
09/2017-0.52NAN/E
06/2017-0.50NAN/E
03/2017-1.38NAN/E
12/2016-1.32NAN/E
09/2016-1.28NAN/E
06/2016-1.30NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.55
Net Inc/Total Assets-0.51Total Liab/Inv Cap0.69
Net Inc/Inv Cap-0.64Total Liab/Comm Equity0.09
Pretax Inc/Net Sales-8.50Interest Coverage RatioNA
Net Inc/Net Sales-8.50Curr Debt/EquityNA
Cash Flow/Net Sales-8.56LTD/Equity-0.03
SG&A/NetSales2.32Total Debt/Equity-0.03
Asset Utilization   Liquidity  
Net Receivables Turnover319.45Quick Ratio4.35
Inventory TurnoverNACurrent Ratio4.35
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.09Inv/Curr AssetsNA
Net Sales/PP&E5.28  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.15 1.60 1.60 1.60
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 6.16 3.85 3.57 3.78
Operating Income -16.20 -13.44 -13.08 -13.01
Interest Exp NA NA NA NA
Pretax Income -16.02 -13.27 -12.70 -12.86
Other Income 0.18 0.16 0.38 0.15
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -16.02 -13.27 -12.70 -12.86

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 51.11 70.95 84.41 97.19
Receivables - Total 0.02 0.02 0.01 0.04
Inventories - Total NA NA NA NA
Total Current Assets 72.12 90.78 114.89 125.13
Net Property, Plant & Equipment 1.24 1.21 1.05 1.06
Total Assets 87.46 105.61 116.56 126.81
Liabilities        
Accounts Payable 9.48 14.33 11.63 9.44
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 10.06 20.86 18.19 15.99
Long-Term Debt 2.47 2.42 2.35 2.48
Total Liabilities 61.57 58.42 57.29 56.85
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.14 0.14 0.14 0.14
Retained Earnings -736.59 -712.44 -699.17 -686.47
Treasury Stock NA NA NA NA
Total Stockholders' Equity -123.15 -96.81 -79.80 -64.27
Total Liabilities and Stockholders' Equity -61.58 -38.39 -22.51 -7.42

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -18.96 -12.16 -12.71 -15.52
Net Cash Provided by Investing Activities -0.15 -0.28 -0.08 -0.03
Net Cash Provided by Financing Activities -0.73 -1.03 0.00 46.30

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.80-57.11-0.66
12/20141.37-31.78-0.31
12/20154.33-120.09-0.96
12/20166.86-165.30-1.32
12/20176.39-54.32-0.53
Growth Rates68.11----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1814658,12140.82




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.